The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

1993 • 396 citations

Autocrine saturation of pro-urokinase receptors on human A431 cells

1986 • 361 citations

Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors.

1990 • 272 citations

Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.

1992 • 239 citations

Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer

1991 • 236 citations

Plasminogen Activation by Receptor-Bound Urokinase

1991 • 214 citations

Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.

1994 • 205 citations

Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma

1994 • 169 citations

Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.

1994 • 167 citations

Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1.

1990 • 147 citations

Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.

1990 • 131 citations

Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines.

1988 • 128 citations

A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

1993 • 122 citations

Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.

1990 • 112 citations

Recombinant soluble urokinase receptor as a scavenger for urokinase‐type plasminogen activator (uPA)

1994 • 101 citations

Plasminogen Activators in Human Prostate Cancer Cell Lines and Tumors: Correlation with the Aggressive Phenotype

1989 • 100 citations

Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes.

1989 • 96 citations

Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor-positive carcinoma cell lines.

1992 • 89 citations

Plasminogen activator system in human breast cancer

1992 • 78 citations

Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma

1990 • 74 citations

Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination

1994 • 64 citations

Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival

1993 • 63 citations

Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer

1994 • 63 citations

Plasminogen activator-specific inhibitors in mouse macrophages: in vivo and in vitro modulation of their synthesis and secretion.

1987 • 60 citations

Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours

1991 • 59 citations

Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.

1992 • 55 citations

Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues

1992 • 54 citations

The correlation between plasminogen activator activity and thymidine incorporation in mouse bone marrow-derived macrophages

1984 • 50 citations

Components of the Plasminogen-Plasmin System in Human Tumor Cell Lines

1991 • 41 citations

Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma.

1989 • 34 citations

Increased Cell‐surface Urokinase in Advanced Ovarian Cancer

1993 • 30 citations

Effects of macrophage-colony stimulating factor on human monocytes: Induction of expression of urokinase-type plasminogen activator, but not of secreted prostaglandin E2, interleukin-6, interleukin-1, or tumor necrosis factor-α

1993 • 30 citations

Plasminogen activator inhibitors in endometrial adenocarcinoma

1993 • 27 citations

Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro

1988 • 27 citations

Immunohistochemical Study of Tumor Cell-associated Plasminogen Activators and Plasminogen Activator Inhibitors in Lung Carcinomas

1993 • 27 citations

Plasminogen activator inhibitors in endometrial adenocarcinoma

1993 • 20 citations

Plasminogen activator content of gynecological tumors and their metastases

1987 • 17 citations

Expression of Colony‐Stimulating Factor‐1 and Its Receptor (the Protein Product of c‐fms) in Invasive Breast Tumor Cells

1993 • 17 citations

Simultaneous stimulation of urokinase and tissue‐type plasminogen activators by phorbol esters in human ovarian carcinoma cells

1989 • 9 citations

Occurrence of the specific plasminogen activator inhibitor of placental type, PAI-2 in ascitic fluid and tumour vessel blood from patients with ovarian carcinoma

1990 • 9 citations

Deleted Work

1955 • 0 citations